Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced, Persistent, or Recurrent Endometrial Cancer
Conditions
Advanced, Persistent, or Recurrent Endometrial Cancer
Trial Timeline
May 21, 2015 → Aug 22, 2024
NCT ID
NCT02228681About Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate is a phase 2 stage product being developed by Novartis for Advanced, Persistent, or Recurrent Endometrial Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02228681. Target conditions include Advanced, Persistent, or Recurrent Endometrial Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced, Persistent, or Recurrent Endometrial Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02228681 | Phase 2 | Completed |
Competing Products
20 competing products in Advanced, Persistent, or Recurrent Endometrial Cancer